EDIT Stock Price Today (October 2026) — Editas Medicine, Inc. Analysis & Key Metrics 2026-10-07
Editas Medicine, Inc. (EDIT) is trading at $2.75, up 0.73% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $5.90 (114.5% upside).
- Volatility is high (54.88% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (232.30% YoY) alongside competitive pressures in the Biotechnology space.
EDIT Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Editas Medicine, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $226.21M
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+114.5% upside potential
Key Investor Questions About EDIT
What investors need to know before buying
Based on current market data, EDIT presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 52.09)
- Fundamentals say: Looking solid (debt and growth supportive)
EDIT's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for EDIT investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $15.51M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, EDIT stock traded between $1.66 and $4.54 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 54.88% annualized volatility and β=2.38, the stock exhibits high sensitivity to market moves—making EDIT suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP shares closed down 6% on Wednesday, while PRME and EDIT stocks declined 12% and 8%, respectively.
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy
Editas Medicine (NASDAQ:EDIT) outlined its strategy as an in vivo gene-editing company and said it remains on track to dose patients this year in a clinical study of its lead program, EDIT-401, for lowering LDL cholesterol. Speaking at the Cantor Healthcare Conference, President and Chief Executive
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion. O’Ne
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna's stock just surged in a way that transforms the company from a cash-burning vaccine maker into a serious acquirer, and four biotech targets already sit within striking range of its newly loaded war chest.
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year?
Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus
Editas beats Q2 estimates as collaboration revenues surge, while EDIT-401 advanced toward clinical testing with encouraging preclinical data.
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Explore More Analysis for EDIT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 9, 2026
Frequently Asked Questions
Common investor questions about Editas Medicine, Inc.
Editas Medicine, Inc. (EDIT) is currently trading at $2.75. The RSI (14-day) is at 52.1, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $5.90 implies 114.5% upside from current levels. Volatility is high at 54.9% annualized, meaning significant price swings are common. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Editas Medicine, Inc. (EDIT): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 3.99. Price-to-Sales is 8.95. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 10 analysts covering EDIT, the consensus price target is $5.90. This represents a 114.5% upside from the current price of $2.75. The range spans from a low target of $1.00 to a high target of $15.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Editas Medicine, Inc. (EDIT) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Editas Medicine, Inc. (EDIT) investors include: 1. High volatility (54.9% annualized)—the stock can experience significant daily price swings. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Elevated short interest (19.5% of float) suggests significant bearish sentiment. 4. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 5. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Editas Medicine, Inc.'s (EDIT) current debt and financial health profile: Total debt stands at $15.51M. The debt-to-equity ratio is 0.15x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.19, indicating strong short-term liquidity. The quick ratio is 3.13. The company holds $211.64M in cash and equivalents. Free cash flow is negative at -$44.32M, which could limit the company's ability to manage debt obligations.